

Polk HealthCare Plan Medical Director Report

TODD WILLS, MD

JANUARY 15, 2016

Plan Dashboard FY 2015


Cost and Utilization



| | Current | Benchmark | | Trend |
|---------------------------------|---------|-----------|---|-------|
| Inpatient | | | | |
| Allowed per Admit | \$7,644 | \$19,065 | ● | 2% |
| Admits per 1,000 | 128.0 | 61.9 | ■ | -4% |
| Days LOS | 3.8 | 4.4 | ● | 9% |
| Outpatient | | | | |
| Allowed per Service | \$44 | \$102 | ● | -1% |
| Services PMPY | 52.1 | 35.7 | ■ | 1% |
| Emergency Room Visits per 1,000 | 492 | 218 | ■ | -2% |
| Prescription Drug | | | | |
| Allowed/Days Supply | \$0.96 | \$2.74 | ● | 19% |
| Days Supply PMPY | 707 | 485 | ■ | 4% |


- Represents a lower than -3% comparison to the benchmark
- ◆ Represents a comparison to the benchmark within +/-3%
- Represents a higher than 3% comparison to the benchmark

Top Medical Conditions by Cost




| | Condition | Allowed Amount Med | Patients Med | Med Allowed /Patient |
|----|--------------------------------|--------------------|--------------|----------------------|
| 1 | Spinal/Back Disord, Low Back | \$742,881 | 1,059 | \$701 |
| 2 | Diabetes | \$695,922 | 1,090 | \$638 |
| 3 | Gastroint Disord, NEC | \$560,639 | 1,011 | \$555 |
| 4 | Hypertension, Essential | \$552,303 | 1,579 | \$350 |
| 5 | Prevent/Admin Hlth Encounters | \$531,292 | 2,119 | \$251 |
| 6 | Respiratory Disord, NEC | \$440,735 | 794 | \$555 |
| 7 | Signs/Symptoms/Oth Cond, NEC | \$431,032 | 1,331 | \$324 |
| 8 | Arthropathies/Joint Disord NEC | \$392,398 | 1,291 | \$304 |
| 9 | Coronary Artery Disease | \$380,316 | 378 | \$1,006 |
| 10 | Infec/Inflam - Skin/Subcu Tiss | \$358,501 | 650 | \$552 |


Screening Rates



Chronic Conditions



Prescription Drug Metrics



| | Therapeutic Class | Allowed Amount Rx | Patients Rx | Rx Allowed /Patient |
|----|--------------------------------|--------------------------|--------------------|----------------------------|
| 1 | Antidiabetic Agents, Insulins | \$924,034 | 392 | \$2,357 |
| 2 | Anticonvulsants, Misc | \$219,722 | 1,124 | \$195 |
| 3 | Sympathomimetic Agents, NEC | \$181,580 | 1,073 | \$169 |
| 4 | Diabetes Mell/Diab Supply NEC | \$176,879 | 585 | \$302 |
| 5 | Psychother, Antidepressants | \$171,700 | 1,858 | \$92 |
| 6 | Antihyperlipidemic Drugs, NEC | \$135,630 | 1,687 | \$80 |
| 7 | Adrenals & Comb, NEC | \$104,940 | 1,017 | \$103 |
| 8 | Analg/Antipyr,Nonstr/Antiinflm | \$73,082 | 2,134 | \$34 |
| 9 | Gastrointestinal Drug Misc,NEC | \$70,026 | 1,020 | \$69 |
| 10 | Antiinflam Agents EENT, NEC | \$53,882 | 581 | \$93 |

Medical Management & Pharmacy and Therapeutics Committee

History of the Committee(s)

- Developed in 2009 at the time of plan restructuring to allow provider voice in newly developed plan services and formulary
- Composed of plan providers, hospital pharmacists, plan administration
- Played an important role at the time of new plan
IMPLEMENTATION

History of the Committee(s)

- Committees have met quarterly since 2010
- Ongoing difficulty in maintaining quorum despite changes in committee members, meeting timing and format
- Two committees merged into one single committee in 2012 for ease of member participation with no change in attendance

Current Function of Committees

- Primarily serve an information dissemination role
- Statistics regarding Pharmacy Benefit Plan costs and Medical Management processes are provided and discussed
- Information provided at the committee is similar in scope in format to that presented at monthly Citizens Oversight Committee meetings
- Minimal role in plan operations

Proposed Changes

- Dissolve existing Pharmacy & Therapeutics and Medical Management Committee
- Continue to provide information disseminated in these committees through the existing Citizens Oversight Committee framework